Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ELEV Elevation Oncology Inc
- Stocks
- Healthcare
- NASDAQ: ELEV
Price (delayed)
$0.382
Market cap
$22.62M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.82
Enterprise value
-$6.62M
Highlights
The EPS has increased by 10% year-on-year but it has declined by 5% since the previous quarter
Elevation Oncology's quick ratio has shrunk by 57% YoY and by 9% QoQ
ELEV's equity is down by 38% year-on-year and by 22% since the previous quarter
Key stats
What are the main financial stats of ELEV
Market
Valuations
Earnings
Shares outstanding
59.22M
Market cap
$22.62M
Enterprise value
-$6.62M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.48
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$49.05M
Net income
-$47.99M
EBIT
-$46.86M
EBITDA
-$46.84M
Free cash flow
-$39.5M
Per share
Balance sheet
Liquidity
EPS
-$0.82
EPS diluted
-$0.82
Free cash flow per share
-$0.67
Book value per share
$0.79
Revenue per share
$0
TBVPS
$1.39
Total assets
$82.22M
Total liabilities
$35.49M
Debt
$31.25M
Equity
$46.73M
Working capital
$77.96M
Debt to equity
0.67
Current ratio
19.4
Quick ratio
19.04
Net debt/EBITDA
0.62
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-48.1%
Return on equity
-74.7%
Return on invested capital
-65.1%
Return on capital employed
-60.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ELEV stock price
How has the Elevation Oncology stock price performed over time
Intraday
0.1%
1 week
0.66%
1 month
35.22%
1 year
-86.16%
YTD
-32.1%
QTD
47.43%
Financial performance
How have Elevation Oncology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$49.05M
Net income
-$47.99M
Gross margin
N/A
Net margin
N/A
Elevation Oncology's operating income has decreased by 27% YoY and by 10% QoQ
ELEV's net income is down by 22% YoY and by 8% QoQ
Price vs fundamentals
How does ELEV's price correlate with its fundamentals
Growth
What is Elevation Oncology's growth rate over time
Valuation
What is Elevation Oncology stock price valuation
P/E
N/A
P/B
0.48
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 10% year-on-year but it has declined by 5% since the previous quarter
ELEV's P/B is 47% below its 5-year quarterly average of 0.9 and 40% below its last 4 quarters average of 0.8
ELEV's equity is down by 38% year-on-year and by 22% since the previous quarter
Efficiency
How efficient is Elevation Oncology business performance
The return on equity has declined by 26% year-on-year and by 20% since the previous quarter
Elevation Oncology's ROA has decreased by 25% YoY and by 15% from the previous quarter
ELEV's ROIC is up by 15% YoY but it is down by 8% QoQ
Dividends
What is ELEV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ELEV.
Financial health
How did Elevation Oncology financials performed over time
The total assets is 132% greater than the total liabilities
Elevation Oncology's current ratio has plunged by 58% YoY and by 9% from the previous quarter
Elevation Oncology's quick ratio has shrunk by 57% YoY and by 9% QoQ
The debt is 33% less than the equity
The debt to equity has soared by 63% YoY and by 29% from the previous quarter
ELEV's equity is down by 38% year-on-year and by 22% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.